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Abstract
CD6 has recently been identified and validated as risk gene for multiple sclerosis (MS), based on the association of a single
nucleotide polymorphism (SNP), rs17824933, located in intron 1. CD6 is a cell surface scavenger receptor involved in T-cell
activation and proliferation, as well as in thymocyte differentiation. In this study, we performed a haptag SNP screen of the
CD6 gene locus using a total of thirteen tagging SNPs, of which three were non-synonymous SNPs, and replicated the
recently reported GWAS SNP rs650258 in a Spanish-Basque collection of 814 controls and 823 cases. Validation of the six
most strongly associated SNPs was performed in an independent collection of 2265 MS patients and 2600 healthy controls.
We identified association of haplotypes composed of two non-synonymous SNPs [rs11230563 (R225W) and rs2074225
(A257V)] in the 2nd SRCR domain with susceptibility to MS (Pmax(T) permutation = 1610
24). The effect of these haplotypes on
CD6 surface expression and cytokine secretion was also tested. The analysis showed significantly different CD6 expression
patterns in the distinct cell subsets, i.e. – CD4+ naı¨ve cells, P= 0.0001; CD8+ naı¨ve cells, P,0.0001; CD4+ and CD8+ central
memory cells, P= 0.01 and 0.05, respectively; and natural killer T (NKT) cells, P= 0.02; with the protective haplotype (RA)
showing higher expression of CD6. However, no significant changes were observed in natural killer (NK) cells, effector
memory and terminally differentiated effector memory T cells. Our findings reveal that this new MS-associated CD6 risk
haplotype significantly modifies expression of CD6 on CD4+ and CD8+ T cells.
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Introduction
Multiple sclerosis (MS) is a disorder of the central nervous
system that is characterized by chronic inflammation, demyelin-
ation, axonal loss and neurodegeneration [1]. Genome-wide
association (GWAS) screens and meta-analyses have enabled
identification of about 50 non-HLA MS risk genes [2–16]. Apart
from the HLA region, the implicated genes exert modest effects at
the population level with odds ratios (OR) ranging from 1.1–1.3
[17]. In a recent study, we validated the association of four risk
single nucleotide polymorphisms (SNPs) with MS susceptibility [5],
in a northern Spanish-Basque population, from which the CD6
SNP rs17824933 emerged with a stronger risk (OR = 1.34) [18].
CD6 is a member of the group B scavenger receptor cysteine-
rich super family (SRCR-SF) [19] found on thymocytes, mature
T-cells, some B-cell and natural killer (NK) subsets and is also
expressed in certain parts of the brain like the cerebellum, basal
ganglia, thalamus, corpus amygdaloideum, and cerebral lobi [20–
23].
At the transcriptional level, in addition to the full-length form, a
total of six isoforms have been reported that diversify the
cytoplasmic domains [24,25]. The ligand for CD6 is the Activated
Leukocyte Cell Adhesion Molecule (ALCAM), found in the thymic
epithelium and in the epithelial layer of the blood-brain barrier.
ALCAM binds to the third SRCR domain of CD6 and this
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interaction was recently shown to enable transmigration of CD4+
T lymphocytes across the blood-brain barrier [26].
Functional studies using mAbs to CD6 have demonstrated its
role in T cell activation, proliferation [27–30] and in regulating the
expression of intracellular phosphoproteins and production of
proinflammatory cytokines [31]. Furthermore, CD6 is involved in
the maturation of the immunological synapse (IS) by associating at
the central supramolecular activation cluster (cSMAC) region
[25]. However, an isoform lacking the ALCAM binding domain,
CD6DD3 which was upregulated upon T cell activation, was not
localized at the IS [25,32]. Studies using thymocytes show an
increased expression of CD6 on thymocytes in the mature (single-
positive) compared to the immature (double-negative, double-
positive) stages and showed the negative influence of CD6 on the
rate of apoptosis implicating its role in thymocyte selection [20].
The CD6DD3 expression was also observed to be higher on
mature compared to immature thymocytes [25].
A recently published [33] correlation analysis of rs17824933
genotypes with expression of two CD6 extracellular domain
isoforms (full-length and CD6DD3) on CD4+ and CD8+ T cells
from healthy donors revealed no significant differences. However,
comparison of the relative expression of the two isoforms showed
the risk allele (rs17824933G) to be associated with a higher
expression of the isoform lacking the ligand binding domain
(CD6DD3).
In the present study, we performed a two-stage CD6 SNP
screen to identify the putative causative variant(s) or haplotypes
that contribute to increased MS susceptibility. We analyzed the
effect of associated haplotypes on the cell surface expression of
CD6 in T and NK cells by flow cytometry and assessed differences
in proliferation and cytokine production (IFN-c and IL-17)
according to haplotype.
Materials and Methods
Sample Collections
The details of the sample collections used for the genetic study
are listed in Table 1. All affected individuals meet established
diagnostic criteria [34,35], and the blood samples were obtained
after written informed consent from all donors, and with the
approval of the institutional ethics research committees from
Bilbao (Comite´ E´tico de Investigacio´n Clı´nica (CEIC) del Hospital
de Basurto), San Sebastia´n (CEIC del Hospital de Donostia),
Madrid (CEIC del Hospital Clı´nico San Carlos-IdISSC), Ma´laga
(CEIC del Hospital Regional Universitario Carlos Haya), Sevilla
(CEIC del Hospital Universitario Virgen Macarena), Granada
(CEIC del Hospital Universitario Virgen de las Nieves), and
UCSF, USA (UCSF Institutional Review Board). Initial screening
was performed using the northern Spanish-Basque dataset, which
includes samples collected from two centers - the Hospital de
Basurto (Bilbao) and the Donostia Hospital (San Sebastia´n). The
replication sample sets included 2265 MS patients and 2600
healthy controls from three different collections – Andalucı´a
(Hospital Virgen Macarena, Sevilla; Hospital Carlos Haya,
Ma´laga; Hospital Clı´nico, Hospital Virgen de las Nieves and
Blood Bank, Granada), Madrid (Hospital Clı´nico S Carlos) and
University of California, San Francisco (UCSF).
SNP Selection and Genotyping
CD6 haplotype-tagging (haptag) SNPs were selected using the
multimarker tagger algorithm from the HapMap website on the
CEU population (r2 cut-off 0.8; MAF 0.2; HapMap Release #27).
A total of a thirteen haptag SNP were selected for the study that
included nine intronic SNPs, three force-included non-synony-
mous SNPs and the rs17824933 reported earlier. A recently
reported SNP, rs650258, located near the CD6 gene which was
found to be strongly associated with MS susceptibility [17], was also
included. Genotyping of the thirteen haptag SNPs was done via
CEGEN (http://www.cegen.org/primera.php?que = presentacio
&lang = cast) using Sequenom technology on the northern Span-
ish-Basque dataset (example of genotype cluster plot in Figure S1).
The Taqman genotyping kits (Life Technologies, Carlsbad, CA) for
the SNPs rs11230548 (ABI custom assay, Forward/Reverse Primer
Sequence: CTAACTTGCTTGGCTAAGGTGTTG/CCACAA-
GATACATGTTAATTACAAAGGAGGAA, Reporter 1/2 Se-
quence: TCTGCTAGATTTATCTGCTG/CTGCTAGATTTC
TCTGCTG), rs17824933 C_33967506_10, rs916811 C_2553017_1,
rs11230559 C_26898776_10, rs11230563 C_31727142_10) were
used with the ABI 7900HT (Life Technologies, USA) in the datasets of
Andalucı´a, Madrid and the UCSF whites, except for the rs2074225,
which was done using the genotyping services of CEGEN or through
sequencing. rs650258 was genotyped using the Taqman assay kit
C_2260876_10 in all the collections. Power was calculated using the
CATS power calculator (http://www.sph.umich.edu/csg/abecasis/
CaTS) [36]. The genotyping success rate for all SNPs was above 95%,
except for the rs916811 and rs11230563 in the Madrid collection that
had success rates of 94% and 94.5% respectively.
Statistical Analysis of Genetic Data
The data obtained was analyzed using PLINK software (version
1.07) http://pngu.mgh.harvard.edu/purcell/plink/[37]. Hardy-
Weinberg equilibrium (HWE) test was performed to check for
deviances among the control population. The strength of
association was assessed via the odds ratio (OR) values in the
individual datasets. The Cochran-Mantel-Haenszel (CMH) test
was done on the replication and combined datasets to test for
association after stratification. A test of heterogeneity (Breslow-
Daystest) was performed on the replication and combined datasets
to identify any heterogeneity. Haplotype analysis for the original
sample set was performed using the Haploview software (version
4.2) [38], and the sliding window analysis and Max-T permutation
P values were calculated using PLINK.
Samples for Fluorescence-activated Cell Sorting (FACS)
and ELISA
10 ml fresh lithium heparinised blood was obtained by
venipuncture from twenty-seven MS patients (Department of
Neurology, Institute of Clinical Neurosciences, Hospital Regional
Universitario Carlos Haya, Ma´laga, Spain) and from twelve
healthy donors (University Klinikum Eppendorf, Hamburg,
Germany). The clinical characteristics of these twenty-seven MS
patients are listed in Table S1. Peripheral blood mononuclear cells
(PBMC) were purified using a Ficoll-Hypaque gradient, as
described in the supplier’s protocol (ICN Biomedicals Inc., OH,
USA), counted and immediately used or cryopreserved in the
presence of dimethyl sulphoxide 10% (v/v) (DMSO), and 20%
fetal bovine serum and stored at 2196uC until further use. When
using frozen samples, PMBC were thawed immediately before use.
Flow Cytometry
The list of monoclonal antibodies (mAb) and their suppliers are
provided in the Table S2. Table S3 gives the details of the
combination of markers used to identify the different cell subsets.
CD3 and CD56 were used to identify T (CD3+ CD562), NK
(CD32 CD56+), and NKT (CD3+ CD56+) cell subsets. Within T
cells, CD4 and CD8 mark T-helper and T-cytotoxic subsets.
Subsequently, CD45RA, CD27 and CD28 were used to
CD6 and Multiple Sclerosis Risk
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distinguish naı¨ve (CD45RA+ CD27+ CD28+), central memory
cells (CD45RA2 CD27+) and effector memory cells (CD45RA2
CD272 CD28+), as well as the terminally differentiated effector
memory cells (TEMRA, CD45RA+ CD272 CD282) [39,40].
Human NK cells can be further divided into the classical cytotoxic
NK CD56dim cells (CD56int CD16+), and the more immune-
regulatory CD56bright (CD56hi CD16) [41]. For staining, PBMCs
were thawed, washed twice, and incubated 45 min with the
antibody cocktails listed in Table S3. Cells were subsequently
washed, re-suspended in 300 ml FACS buffer and analyzed on a
FACS Canto flow cytometer (BD Bioscience, San Diego, CA).
FACS Diva software version 6.1.3 (BD Bioscience, San Diego, CA)
was used to analyze the raw data.
Cell Culture, Proliferation and ELISA Assays for Cytokine
Measurement
PBMCs (106 cells) from each donor were suspended in 500 ml of
RPMI (GIBCO, Life technologies, USA) containing 5% FBS
(Biochrom AG, Germany), aliquoted into a 48-well plate (Greiner
Bio-One Ltd., UK) and cultured under three different conditions:
unstimulated, stimulated with anti-CD3 (OKT3, 100 ng/ml) with
or without anti-CD6 mAb (161.8, concentration 10 mg/ml) (Kindly
provided by Prof. Francisco Lozano, IDIBAPS, Facultat de
Medicina, Universitat de Barcelona, Barcelona). To determine
cell proliferation, PBMC from healthy donors were labeled with
2 mM eFluor670 (eBioscience) according to the manufacturer’s
protocol. In brief, eFluor stock reconstitution and dilutions were
done in PBS at 4uC and incubation with the dye was performed at
room temperature (RT) for ten minutes. To stop labeling,
standard medium was added and incubated on ice for five
minutes. Labeled cells were then transferred into 48-well plates
with the respective stimuli for further cell culture. Cells were
counterstained with specific lineage markers to assess proliferation
at day 0 and 3 by assessing the percentage of cells that had
undergone division determined by flow cytometry. The superna-
tants from the culture were collected on the third day and
quantified for the cytokines IL-17 and IFN-c using Ready-Set-Go
ELISA kits (eBiosciences, San Diego, CA, USA). The cytokine
concentration (pg/ml) was calculated using the standard curves
generated using the respective standards.
Statistical Analysis of FACS and ELISA Data
ANOVA and two-tailed Student’s-t test were used to calculate
the differences in surface expression, while differences in
proliferation and cytokine production between the different
haplotypes were assessed by the non-parametric Mann-Whitney
U test using Graphpad Prism software version 5 (GraphPad
Software, La Jolla, CA).
Results
A CD6 Haplotype Containing Two Non-synonymous SNPs
in the 2nd SRCR Domain is Associated with MS
The first stage of the study was performed on a dataset from
northern Spain (Basque Country) constituting a total of 823 MS
patients and 814 healthy controls. Nine haplotype tagging (haptag)
SNPs (Hapmap release 27) were selected to cover CD6 gene
variability. Three further non-synonymous SNPs were included –
rs11230563 (R225W) and rs2074225 (A257V) in the second
SRCR domain (Exon 4) and rs12360861 (A271T) in the third
SRCR domain (Exon 5). In addition, rs17824933 [5,18] and
rs650258 [17] were also included (Figure 1). Thirteen SNPs are
situated in the extracellular domain region, which is divided into
two linkage disequilibrium (LD) blocks by a recombination spot
with a maximum recombination rate of 21.9 cM/Mb (at position
60514919, Hapmap release #27) (Figure 1), while rs650258
(position 60588858, recombination rate 3.22, Hapmap #27) is
located between CD6 and CD5 on a recombination peak with
maximum rates of 11.12 cM/Mb (at position 60584694,) and
31.4 cM/Mb (at position 60592693) respectively.
Six SNPs were found to be associated with MS susceptibility at
nominal significance levels (Table 2), and were replicated in a total
of 2265 MS patients and 2600 healthy controls from three
different collections (Table 1). One additional non-synonymous
SNP rs11230563 (R225W) was also included as it demonstrated a
trend towards association (P= 0.08, OR = 1.13) in the first-stage
screen. Three SNPs emerged with nominal significance from the
Table 1. Clinical characteristics of the MS patients included in the genetic study.
NORTHERN SPANISH-BASQUE REPLICATION DATASET
BILBAO SAN SEBASTIA´N UCSF WHITES ANDALUCI´A MADRID
Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases
Participants
Total number 565 573 249 250 450 507 1340 1119 810 639
% Male/Females 31.2/68.8 26.5/73.5 34/66 38/62 32.9/67.1 32/68 27.3/62.7 26.8/62.5 45.4/53.2 34.7/62.8
/Unknown /0 /0 /0 /0 /0 /0 /0 /10.7 /1.4 /2.5
Disease course (%)
RR & SP/PP/PR – 87.6/10/0 – 88/2/0/ – 79.7/3.1/0.4/
16.8/0
– 82.2/1/0.3
0.5/15.9
– 83.3/9.7/0.1
/other/no details /1.6/0.8 /0.8/9.2 /0.5/6.4
Age at Onset
Mean 6 S.D. – 30.5610.10 – 31.6610.3 – 33.369.3 – 29.469.9 – 28.968.9
EDSS
Mean 6 S.D – 3.0862 – 3.9162.6 – 2.0461.96 – 3.261.8 – 2.962.3
Abbreviations: RR = Relapsing-remitting, SP = Secondary progressive, PP = Primary progressive, PR = Primary relapsing, S.D. = Standard deviation.
doi:10.1371/journal.pone.0062376.t001
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replication set; rs17824933, rs11230559 and rs2074225 (Table 3).
Combined analysis of all datasets showed association of
rs11230559, rs2074225, rs17824933 and rs650258.
Analysis of LD patterns revealed that rs11230559 is in strong
LD with rs17824933 SNP in the northern Spanish dataset
(D’= 0.99, r2 = 0.93; Figure 2), and also in the combined dataset
(not shown), in agreement with data from the 1000 Genomes
Project (D’= 1, r2 = 0.85; Figure 2). Both these SNPs are in strong
LD with two non-synonymous SNPs – rs11230562 (T217M) in the
SRCR domain 2 (Exon 4) (D’= 1, r2 = 0.94 with rs17824933 and
D’= 1, r2 = 0.8 with rs11230559) and rs2074233 (G606S) in the
cytoplasmic domain (Exon 11) (D’= 0.94, r2 = 0.84 with
rs17824933 and D’= 1, r2 = 0.898 with rs11230559). However,
rs650258 showed limited or no LD with any of the three non-
synonymous SNPs rs11230563 (D’= 0.224, r2 = 0.038), rs2074225
Figure 1. Locations of the 14 Stage 1 SNPs and their linkage disequilibrium (LD) patterns at the CD6 locus. (A) LD block images with the
approximate locations of the 14 SNP markers chosen for this study, recombination spots and LD patterns within the CEU LD plot (Hapmap, version
27) of the CD6 gene, and (B) LD patterns in the northern Spanish-Basque population using the confidence interval method (Gabriel et al. [54];
generated using the Haploview software).
doi:10.1371/journal.pone.0062376.g001
Table 2. Association analysis of 14 CD6 SNPs in the northern Spanish-Basque dataset.
SNP ID
POWER(1)
(%) BP LOCATION
AA
CHANGE
MINOR/MAJOR
ALLELE (2) HWE P-VALUE FREQ.
(3) (4)
P-VALUE OR (95% CI) (3)
CASES/CNT CASES/CNT
rs3019561 96 60500429 Intron 1 – T/G 0.93/0.92 0.25/0.24 0.44 1.07 (0.91 – 1.25)
rs3019562 99 60501644 Intron 1 – C/G 0.67/0.32 0.51/0.47 0.04 1.16 (1.01 – 1.33)
rs3019548 97 60505515 Intron 1 – G/A 0.83/0.6 0.40/0.38 0.16 1.11 (0.96 – 1.28)
rs2905506 95 60506624 Intron 1 – T/C 0.72/1 0.26/0.25 0.36 1.08 (0.92 – 1.26)
rs11230548 95 60508145 Intron 1 – A/C 0.9/0.55 0.86/0.82 0.008 1.28 (1.06 – 1.56)
rs17824933 94 60517188 Intron 1 – G/C 0.73/0.09 0.29/0.25 0.007 1.24 (1.06 – 1.45)
rs11230555 92 60519710 Intron 1 – A/C 0.84/0.62 0.78/0.77 0.57 1.05 (0.89 – 1.25)
rs916811 97 60520408 Intron 1 – A/G 0.46/0.66 0.79/0.72 3.361025 1.40 (1.21 – 1.63)
rs11230559 95 60526110 Intron 1 – C/T 0.87/0.14 0.30/0.25 0.004 1.25 (1.07 – 1.46)
rs2237997 98 60528666 Intron 1 – C/T 0.30/0.015 0.38/0.35 0.07 1.14 (0.99 – 1.32)
rs11230563 98 60532785 Exon 4 R225W T/C 0.12/0.82 0.40/0.36 0.08 1.13 (0.98 – 1.31)
rs2074225 99 60532882 Exon 4 A257V C/T 0.55/0.94 0.71/0.63 3.161026 1.40 (1.21 – 1.63)
rs12360861 75 60533649 Exon 5 A271T A/G 0.36/0.43 0.81/0.81 0.79 1.03 (0.85– 1.21)
rs650258(5) – 60588858 39 Intergenic T/C 0.2/0.06 0.56/0.51 0.0052 1.23 (1.06–1.41)
(1)Power was calculated with an OR=1.34 based on the original OR for rs17824933 in the Spanish-Basque dataset [18] using the CEU frequencies (NCBI) for each SNP.
(2)The risk alleles are underlined.
(3)Values represented in terms of the risk allele.
(4)Genotyping success rates were above 95% for all the SNPs typed.
(5)rs650258 was included based on the association observed in a recent genome–wide screen in MS [17].
doi:10.1371/journal.pone.0062376.t002
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(D’= 0.095, r2 = 0.005) and rs12360861 (D’= 1, r2 = 0.149) (http://
www.broadinstitute.org/mpg/snap/ldsearch.php) [42].
Haplotype analysis was performed on all datasets. A sliding
window analysis using two, three and four markers was done
followed by 10K max(T) permutation analysis. Furthermore, two-
and three-marker analysis using at least one of the two non-
synonymous SNPs was also performed (Table S4). The max(T)
permutation performs multiple correction based on the number of
SNPs tested, while taking account of their correlation (LD) structure.
The sliding window analysis showed stronger association (OMNI-
BUS) of combinations including both the exonic non-synonymous
SNPs rs11230563 and rs2074225 (P max(T) permutation = 1610
24), and
of rs2074225 and rs650258 (P max(T) permutation = 1610
24)
(Figure 3, Table S4). Addition of rs17824933 or rs11230559 to
the haplotype markers rs11230563-rs2074225 did not signifi-
cantly alter the haplotype frequencies (Table S5) or increase the
strength of association (data not shown), indicating that the
association was in essence explained by the haplotype
rs11230563-rs2074225 (P max(T) permutation = 1610
24) (Figure 3,
Table S4). The use of aggressive tagging on two-marker and
three-marker haplotypes showed that rs11230563 could be
tagged by markers rs916811 and/or rs11230559 along with
rs2074225 (r2 = 0.946) and also by rs916811 and/or rs17824933
with rs2074225 (r2 = 0.892). Similarly, the SNP rs2074225 was
Table 3. Replication and combined analysis of the most significant SNPs.
REPLICATION COMBINED
SNPs (1) PCMH P BD OR
(2) (95% CI) PCMH P BD OR
(2) (95% CI)
rs11230548 (A/C) 0.64 0.25 0.97 (0.85–1.1) 0.85 0.17 1.01 (0.90–1.13)
rs17824933 (G/C) 0.02 0.44 1.14 (1.02–1.27) 0.005 0.58 1.16 (1.04–1.28)
rs916811 (A/G) 1.00 0.49 1 (0.89–1.13) 0.45 0.32 1.04 (0.94–1.16)
rs11230559 (C/T) 0.02 0.20 1.14 (1.02–1.27) 0.005 0.31 1.15 (1.05–1.27)
rs11230563 (T/C) (3) 0.77 0.69 0.98 (0.89–1.09) 0.88 0.83 0.99 (0.91–1.09)
rs2074225 (C/T) 0.03 0.53 1.14 (1.01–1.25) 0.0065 0.67 1.14 (1.04–1.25)
rs650258 (T/C)(4) 0.08 0.46 1.085 (0.99–1.19) 0.003 0.30 1.12 (1.04–1.21)
Abbreviations: CMH=Cochran-Mantel-Haenszel test, BD = Breslow-Day test, OR =Odds ratio, CI = Confidence interval.
(1)The risk alleles (with respect to the Basque dataset) are underlined.
(2)The ORs are represented for the risk alleles found in the first-stage screen.
(3)rs11230563 was included because it is a non-synonymous SNP that substitutes R225W, and showed a trend towards association in the first stage screen.
(4)rs650258 was included based on the association observed in the Basque dataset.
doi:10.1371/journal.pone.0062376.t003
Figure 2. LD values (D’/r2 values) between each of the 14 SNP markers genotyped in the Spanish-Basque population. The figure
represents a comparison of the LD values between the 14 SNPs genotyped in the northern Spanish-Basque population (D’/r2 values) using the values
from the CEU 1000 genomes project and from the data generated from the Spanish-Basque population (823 cases/814 controls). The values in white
are the D’/r2 values from the CEU 1000 Genomes Project, while the blue-shaded ones are generated for the northern Spanish-Basque dataset using
Haploview software (version 4.2).
doi:10.1371/journal.pone.0062376.g002
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tagged by the markers rs11230563 and rs11230559/rs17824933
(r2 = 0.937/0.882 respectively). This indicated that the two non-
synonymous SNPs could be tagged by the intronic SNPs in
combination with either of the non-synonymous SNP.
A logistic regression analysis was performed assuming additive
affects of allele dosage to test for independent effects. The analysis
revealed independent effects exerted by the SNPs rs2074225 and
rs650258, and conditioning rs11230563 with rs2074225 showed
strong additive effects with P= 6.261027 (Table S6).
In summary, we identified two novel SNPs associated with MS
risk, that is, rs11230559 located in the intronic region, and
rs2074225, a non-synonymous SNP located in the 2nd SRCR
domain, and validated the association of rs650258 [17] with
susceptibility to MS. Sliding window haplotype analysis revealed
strong association of the two domain-2 (Exon-4) non-synonymous
SNPs, which was confirmed by logistic regression analysis.
The rs11230563-rs2074225 CD6 Haplotype Modifies CD6
Expression on CD4+ and CD8+ Naı¨ve T Cells
FACS analysis was performed on lymphocytes of MS patients
genotyped for both CD6 markers SNPs rs11230563 and
rs2074225. CD6 was expressed at very high levels on all CD4+
T cell subsets, and to a lesser extent on CD8+ and NKT cells
(Figure 4, Figure S2). In these three lymphocyte subsets, CD6
expression levels varied significantly, – with the protective
haplotype (rs11230563-rs2074225) CC expressing higher CD6
levels than both the risk haplotype CT and the TT haplotype that
provides mild risk (Figure 4). These differences were prominent
among the CD4+ (PANOVA = 0.0008) and CD8
+ (PANOVA = 0.001)
lymphocytes, but were also observed in NKT cells (PA-
NOVA = 0.02). Upon separation of the CD4
+ and CD8+ cell
subsets according to their naı¨ve, memory or effector phenotypes,
we found the greater differences in the naı¨ve (CD4+ naı¨ve cells,
PANOVA = 0.0001; CD8
+ naı¨ve cells, PANOVA ,0.0001), and the
CD4+ central memory subset (PANOVA = 0.01), while no differ-
ences were found in the effector subsets and in the terminally
differentiated effector cells (CD272 CD282) cells (Figure 4). Of
note, NKT cells also expressed CD6, and the haplotype-related
differences were also observed in this population (PANOVA = 0.02).
NK cells expressed much lower levels of CD6 on their surface, and
no significant changes in expression were observed in relation to
the CD6 haplotypes. Similar observations were made when the
non-synonymous SNPs were analyzed individually (Figure S3, S4).
Haplotype-specific Differences in Proliferation and
Cytokine Secretion upon T-cell Stimulation
The differential expression of CD6 from the different genotypes
and haplotypes points to a possible effect on T cell function.
Further experiments were aimed at identifying differences in
proliferation and in cytokine production. Polyclonally stimulated
T cells were assessed to determining whether co-stimulation of
CD6 using specific antibodies had a haplotype-related effect on
proliferation and on cytokine production. For this purpose,
PBMCs were stimulated with anti-CD3 in the presence or absence
of anti-CD6 161.8 mAb. Our data showed no significant
differences in proliferation and in the levels of IFN-c and IL-
17A secretion between the haplotypes or different conditions
(Figure S5). However, even though not significant, donors with the
CC haplotype showed relatively higher proliferation and higher
levels of IL-17A than those with the CT haplotype. Furthermore,
co-stimulation with the anti–CD6 mAb, 161.8 showed a mild
decrease in proliferation and IL-17A production (Figure S5).
Discussion
In this study, we aimed to identify the most important MS-
associated CD6 SNP variants through a fine-mapping exercise.
Our data showed a strong association of a non-synonymous SNP
rs2074225 with susceptibility in the Spanish-Basque dataset that
was replicated in the combined dataset (Table 2, 3). Furthermore,
the analysis also revealed association of rs17824933 and
rs11230559, both of which are in strong LD with each other
(r2.0.8) and with two other non-synonymous SNPs located in
exon 4 (rs11230562) and exon 11 (rs2074233). The association of
these SNPs was observed to be stronger in the original dataset
(Spanish-Basque residents) when compared to the replication sets;
and this may be related to factors such as disease heterogeneity,
and the relatively high degree of genetic homogeneity in the
Spanish Basque geographic sampling area [43].
Haplotype analysis using sliding window and two-marker
approaches implicated a role of two non-synonymous SNPs
rs11230563 (R225W) and rs2074225 (A257V). We analyzed
Figure 3. Sliding window haplotype analysis using (A) two and (B) three markers by means of max(T) permutation analysis. A sliding
window analysis tests the overall association of the two/three markers that are located adjacent to each other shifting one marker at a time. The
analysis was done using the combined dataset containing 3088 cases/3414 controls from the three replication sample sets and the original dataset
for the six SNPs selected for replication.
doi:10.1371/journal.pone.0062376.g003
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expression changes of CD6 on different immune cell types
according to genotypes for the individual non-synonymous SNPs
genotypes or their haplotypes. Our screen included, apart from the
CD4+ and CD8+ T-cells studied by Kofler et al., [33], also NK
cells, NKT cells, and T-effector cell subsets in an attempt to
identify the cell type more strongly influenced by the CD6 non-
synonymous SNP genotype/haplotype. Since the mAb used in this
study for FACS targets the SRCR domain 1 region, discrimination
between different isoforms was not possible. Our data showed a
more pronounced effect of the rs11230563-rs2074225 haplotype
compared to the individual non-synonymous SNPs (Figure 4,
Figure S3, S4). The expression trends showed the protective
haplotype (CC) to yield higher surface expression of CD6 when
compared to the risk haplotypes (CT and TT), which is in
agreement with both the trends observed by Kofler et al. on the
full length isoform [33] and the analysis of Heap et al., [44] who
reported allele imbalances of eight SNPs in the CD6 region
including rs2074225, rs11230562, and - as inferred though LD
patterns, rs17824933.
We also observe that the expression of CD6 from the TT (mild
risk) haplotype cells was lower than that from the CT (risk)
haplotype. While the CT haplotype is intermediate in terms of
CD6 expression between the protective (CC) and mild risk (TT)
haplotype in the CD4+ and CD8+ T cells, its expression shows a
non-significant trend to be higher in CD4+ and CD8+ effector
memory T cells. Thus, our data suggests that this CD6-conferred
genetic risk is complex and may result in changes in both CD6
expression levels and ligand binding or signal transduction via the
non-synonymous SRCR domain 2 SNPs rs11230563 (R225W)
and rs2074225 (A257V) in addition to the cytoplasmic domain
SNP rs2074233 (G606S).
The contribution of the isoform lacking the ligand-binding
domain (CD6DD3), of which expression is inversely correlated
with that of the full-length form [33], should be factored in
into the elucidation of CD6 function. Kofler et al., [33] observed
no significant differences in CD6 expression of the full length
form between genotypes, but reported increased relative expres-
sion of CD6DD3 in both CD4+ and CD8+ T-cells in individuals
homozygous for the risk allele rs17824933GG. In our study,
the naı¨ve CD4+ and CD8+ T-cell populations were more strongly
affected by the CD6 haplotype than effector and central memory
cells. This is important as CD6 is highly expressed in thymic
cells and is thought to aid positive selection and provide
resistance to apoptosis [20]. Furthermore, Singer et al. [20]
and Castro et al. [25] showed the two isoforms to be more highly
expressed on mature cells. In the thymus, CD6DD3 is under-
expressed in the double-positive cells, while the expression of
the full-length form is favored which contributes to their
survival.
In addition, being a member of the scavenger family, both the
isoforms of CD6 appear to bind to bacteria, and may act
therefore in an early infectious phase putatively associated with
onset of MS, even if the precise mechanism is as yet unknown.
Binding studies with LPS and anti-CD6 mAbs showed phos-
phorylation of ERK1/2 and p38 MAPK indicating activation of
the MAPK pathway [45,46]. Observation of proliferation and
cytokine secretion patterns showed a trend towards reduced
proliferation by the risk haplotype when compared to the
protective haplotype. These findings are in league with the
findings of Kofler et al. [33], who observed reduced cell
proliferation among the donors with the risk genotype
rs17824933GG. Similar trends to that of proliferation were
observed with IL-17, where higher levels of this cytokine were
observed with the protective haplotype (CC) than with the risk
haplotype (CT) (not-significant trend; Figure S5). Since addition
of anti-CD6 did not significantly alter the proliferation rate and
the production of cytokine, it could be inferred that the anti-CD6
mAb could lead to generalized blocking of proliferation and
cytokine production and is not SNP-dependent. The IL-17
trends, though inconclusive, do suggest that allelic variation in
CD6 may be associated with altered cytokine secretion from
Th17 cells. Given the capability of CD6 to bind to bacteria/LPS
[45], and the evidence for a role of IL-17A in mediating
protection against various pathogens [47,48], this may be of
relevance to the concept of infectious agents acting as triggers for
MS. Alternatively, observation of higher IL-17A levels among
those with the protective haplotype could indicate a protective/
anti-inflammatory role of IL-17A. The ability of IL-17A to
protect against development of autoimmune uveitis and ulcera-
tive colitis [49,50] has been demonstrated; however, this contrasts
with the reported disease-promoting role of Th17 cells in MS
[51–53], and will need further clarification.
Taken together, our results indicate that non-synonymous
polymorphic variations in the 2nd SRCR domain are associated
with functional changes. Screening of the different cell types
showed the most significant expression differences in CD4+ and
CD8+ naı¨ve cells, suggesting that phenotypic expression of CD6
variation may affect the early stages of cell-mediated immune
responses.
Supporting Information
Figure S1 Plots showing Sequenom-based clustering of the
alleles from the dataset of Bilbao. Each of the axes represents an
allele and each sample in the graph is represented as a dot.
Samples homozygous for any of the alleles fall near the x or y-axis
while the heterozygotes lie in the graph area between the two axes.
(TIF)
Figure S2 FACS-gating strategy. PBMCs were stained with
anti-CD3, CD56, CD16, CD4, CD8 and CD6 antibodies. After
gating on lymphocytes, the T and NK cell subsets were defined as
shown in the top left panel. From the NK cells, NKbright and
NKdim cells were identified according to the level of CD56 and
the presence of CD16. T-helper and T cytotoxic lymphocytes
were identified by CD4 and CD8 staining, respectively. In these
two populations, CD45RA and CD27 were used to define naive,
effector and memory cell subsets, as indicated in the two top right
panels. The lower panels show the corresponding histograms
depicting the expression of CD6 in each of the forementioned
subsets. NK histogram, solid line indicates NKbright and dashed
Figure 4. CD6 expression on different cell types segregated by non-synonymous CD6 haplotypes, as analyzed by FACS. A total of
27 PBMC samples representing each of the three haplotypes from the two non-synonymous SNPs rs11230563 and rs2074225 were analysed for CD6
expression on the different cell subsets. The y-axis represents the median fluorescence intensity (MFI) while the x-axis represents the three different
haplotypes; i.e. the CC haplotype that confers protection, CT associated with risk and TT conferring mild risk. The distinct subpopulations were
identified using different surface markers as listed in Table S4. The markers CD3 and CD56 were used to identify T cells (CD4+/CD8+ CD3+ CD562), NK
(CD32 CD56+), and NKT (CD3+ CD56+) cell subsets; CD45RA, CD27 and CD28 were used to distinguish naı¨ve (CD45RA+ CD27+ CD28+), central memory
cells (CD45RA2 CD27+) and effector memory cells (CD45RA2 CD272 CD28+), as well as the terminally differentiated effector memory cells (TEMRA,
CD45RA+ CD272 CD282); while CD56 and CD16 were used to identify the NK CD56dim (CD56int CD16+) and the CD56bright (CD56hi CD16) cells.
doi:10.1371/journal.pone.0062376.g004
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line NKdim cells; T cells, solid line indicates CD4 and dashed
line CD8 cells; in the CD4 and CD8 histograms, solid line
indicates naive cells (N), dotted line effector memory cells (EM)
and dashed line central memory cells (CM).
(TIF)
Figure S3 Comparison of CD6 expression on the different cell
types with respect to rs11230563 genotypes.
(TIF)
Figure S4 Comparison of CD6 expression on the different cell
types with respect to rs2074225 genotypes.
(TIF)
Figure S5 Comparison of proliferation and cytokine levels (pg/
ml) between the three haplotypes. PBMCs representing each of the
haplotypes (CC = protective, CT = high risk, TT = mild risk) from
the healthy donors were cultured in a 48-well plate for three
different stimulatory conditions – unstimulated, OKT3 stimulated
(100 ng/ml) with/out anti-CD6 161.8 (10 mg/ml). Proliferation
was assessed by measuring 106 cells stained with eFluor670 on the
third day of culture. The supernatant collected from the three-day
culture was used to quantify IL-17A and IFN-c using ELISA.
Each column represents the mean values of the samples.
Comparison of proliferation rates and cytokine production was
done by the non-parametric Mann-Whitney-U test using Graph-
pad software (version 5).
(TIF)
Table S1 Demographic and clinical variables of the PBMC
samples collected from MS patients for the functional study.
(DOC)
Table S2 Details of the monoclonal antibodies used in flow
cytometry.
(DOC)
Table S3 The combination of monoclonal antibodies used for
cell surface staining.
(DOC)
Table S4 OMNIBUS association P-values of haplotypes gener-
ated using sliding window or multiple marker analysis on the
merged datasets.
(DOC)
Table S5 Comparison of the haplotype frequencies in the four
datasets of (A) the 2 associated NS haplotype SNP markers, or (B)
three NS SNP markers.
(DOC)
Table S6 Logistic regression analysis on the combined dataset
showing additive effects of the SNPs when conditioned to
rs11230563, rs2074225 and rs650258.
(DOC)
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